As of Jul 22
| -0.008 / -2.19%|
The 1 analysts offering 12-month price forecasts for CTi Biopharma Corp have a median target of 0.75, with a high estimate of 0.75 and a low estimate of 0.75. The median estimate represents a +110.20% increase from the last price of 0.36.
The current consensus among 3 polled investment analysts is to Hold stock in CTi Biopharma Corp. This rating has held steady since July, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.